Therefore, our results reveal the role of CTHRC1 in CAFs in pancreatic cancer, and the CTHRC1/LIF/STAT3 signaling axis may be a promising prognostic marker and therapeutic target for patients with pancreatic cancer. This evidence concerns the gene CTHRC1 and familial pancreatic carcinoma.